SG Americas Securities LLC lifted its position in Incyte Co. (NASDAQ:INCY) by 406.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 111,187 shares of the biopharmaceutical company’s stock after purchasing an additional 89,214 shares during the quarter. SG Americas Securities LLC owned 0.05% of Incyte worth $8,253,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Commonwealth Bank of Australia grew its holdings in Incyte by 49.2% during the 2nd quarter. Commonwealth Bank of Australia now owns 376 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 124 shares during the last quarter. Pathstone Family Office LLC bought a new stake in Incyte during the 2nd quarter worth about $34,000. Captrust Financial Advisors bought a new stake in Incyte during the 2nd quarter worth about $35,000. First Manhattan Co. bought a new stake in Incyte during the 2nd quarter worth about $50,000. Finally, CSat Investment Advisory L.P. grew its holdings in Incyte by 180.5% during the 2nd quarter. CSat Investment Advisory L.P. now owns 676 shares of the biopharmaceutical company’s stock worth $58,000 after acquiring an additional 435 shares during the last quarter. 91.70% of the stock is currently owned by institutional investors and hedge funds.

In related news, EVP Paula J. Swain sold 2,500 shares of the firm’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $80.00, for a total value of $200,000.00. Following the completion of the transaction, the executive vice president now directly owns 44,112 shares of the company’s stock, valued at $3,528,960. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Yao Wenqing sold 2,040 shares of the firm’s stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $85.00, for a total transaction of $173,400.00. Following the completion of the transaction, the executive vice president now directly owns 47,348 shares of the company’s stock, valued at $4,024,580. The disclosure for this sale can be found here. Insiders sold 94,294 shares of company stock valued at $7,849,355 over the last three months. 17.10% of the stock is owned by company insiders.

Shares of NASDAQ:INCY traded up $2.34 during mid-day trading on Friday, reaching $85.10. The stock had a trading volume of 870,200 shares, compared to its average volume of 1,276,004. Incyte Co. has a twelve month low of $57.00 and a twelve month high of $89.30. The company has a current ratio of 5.02, a quick ratio of 5.01 and a debt-to-equity ratio of 0.02. The firm has a 50 day simple moving average of $78.24 and a two-hundred day simple moving average of $80.22. The firm has a market cap of $18.12 billion, a PE ratio of 103.78, a price-to-earnings-growth ratio of 1.23 and a beta of 0.99.

Incyte (NASDAQ:INCY) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.27. Incyte had a net margin of 19.21% and a return on equity of 20.07%. The business had revenue of $551.58 million during the quarter, compared to analysts’ expectations of $534.73 million. During the same period last year, the business earned $0.41 earnings per share. The firm’s revenue was up 22.7% on a year-over-year basis. On average, equities analysts anticipate that Incyte Co. will post 2.14 EPS for the current fiscal year.

A number of equities research analysts have commented on INCY shares. JMP Securities increased their price objective on shares of Incyte from $107.00 to $110.00 and gave the stock a “market outperform” rating in a report on Monday, September 30th. Guggenheim set a $101.00 target price on shares of Incyte and gave the company a “buy” rating in a research report on Friday, September 27th. Nomura upped their target price on shares of Incyte from $100.00 to $111.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. BMO Capital Markets began coverage on shares of Incyte in a research report on Thursday, September 12th. They set a “market perform” rating and a $85.00 target price on the stock. Finally, JPMorgan Chase & Co. restated a “buy” rating and set a $91.00 target price on shares of Incyte in a research report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Incyte currently has an average rating of “Buy” and a consensus target price of $92.90.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Read More: What is meant by buying and selling pressure?

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.